163 related articles for article (PubMed ID: 29848094)
1. Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice.
Pérez Cabeza AI; González Correa JA; Chinchurreta Capote PA; Bravo Marqués R; Ruiz Mateas F; Rosas Cervantes G; Mesa Prado F; López Tejero S; Valle Alberca A
Future Cardiol; 2018 May; 14(3s):9-16. PubMed ID: 29848094
[TBL] [Abstract][Full Text] [Related]
2. Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain.
Martí E; Segado A; Pastor-Galán I; Amat P; Remigia MJ; Solano C; Navarro B
Future Cardiol; 2018 May; 14(3s):3-8. PubMed ID: 29848095
[TBL] [Abstract][Full Text] [Related]
3. Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice.
Brun Guinda D; Callen García Ó; Ondiviela Pérez J; Gracia Aznarez M; Artero Bello P; Rivero Fernandez E; Marquina Barcos A; Villarroel Salcedo M
Future Cardiol; 2018 May; 14(3s):39-45. PubMed ID: 29848090
[TBL] [Abstract][Full Text] [Related]
4. Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain.
Muñiz Lobato S; Tarrazo Tarrazo C; González Fernández E; Morán Alcalá M
Future Cardiol; 2018 May; 14(3s):17-24. PubMed ID: 29848093
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke.
Cerezo-Manchado JJ; Navarro-Almenzar B; Elvira-Ruiz G; García-Candel F; Flores-Blanco PJ; Caro-Martínez C; Manzano-Fernández S; García-Iniesta N; Sánchez-García J; Cabañas-Perianes V; Moraleda-Jiménez JM
Future Cardiol; 2018 May; 14(3s):31-37. PubMed ID: 29848091
[TBL] [Abstract][Full Text] [Related]
6. Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?
Pimentel Quezada Y; Bonilla Palomas JL; Gámez López AL; Moreno Conde M; López Ibáñez MC; Gallego de la Sacristana López-Serrano Á
Future Cardiol; 2018 May; 14(3s):47-53. PubMed ID: 29848089
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulation with rivaroxaban in a hematology unit: clinical profile, events and discontinuation rates in real-life patients with nonvalvular atrial fibrillation.
Gavín Sebastián O; Izuzquiza Fernández M; Martínez Fernández R; Palomera Bernal L
Future Cardiol; 2018 May; 14(3s):25-30. PubMed ID: 29848092
[TBL] [Abstract][Full Text] [Related]
8. CHA
Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
Caro Martinez C; Cerezo Manchado JJ; Flores Blanco PJ; Elvira Ruíz G; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Andrés Pascual Figal D; Bailén Lorenzo JL; Navarro-Almenzar B; García-Candel F; Manzano Fernández S
Curr Med Res Opin; 2019 Aug; 35(8):1463-1471. PubMed ID: 30912682
[No Abstract] [Full Text] [Related]
10. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Graham DJ; Reichman ME; Wernecke M; Hsueh YH; Izem R; Southworth MR; Wei Y; Liao J; Goulding MR; Mott K; Chillarige Y; MaCurdy TE; Worrall C; Kelman JA
JAMA Intern Med; 2016 Nov; 176(11):1662-1671. PubMed ID: 27695821
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban: from ROCKET-AF trial to routine practice in Spain.
Escobar Cervantes C
Future Cardiol; 2018 May; 14(3s):1-2. PubMed ID: 29848088
[No Abstract] [Full Text] [Related]
12. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
Engelberger RP; Noll G; Schmidt D; Alatri A; Frei B; Kaiser WE; Kucher N
Eur J Intern Med; 2015 Sep; 26(7):508-14. PubMed ID: 25935131
[TBL] [Abstract][Full Text] [Related]
13. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Kuhls S; van Eickels M; Turpie AG;
Eur Heart J; 2016 Apr; 37(14):1145-53. PubMed ID: 26330425
[TBL] [Abstract][Full Text] [Related]
14. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].
Colonna P; Ammirati F;
G Ital Cardiol (Rome); 2016 Nov; 17(11):932-939. PubMed ID: 27996999
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
16. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
[TBL] [Abstract][Full Text] [Related]
17. The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Shimokawa H; Yamashita T; Uchiyama S; Kitazono T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Sakuma I; Saku K; Okumura Y; Nakamura Y; Morimoto H; Matsumoto N; Tsuchida A; Ako J; Sugishita N; Shimizu S; Atarashi H; Inoue H
Int J Cardiol; 2018 May; 258():126-132. PubMed ID: 29429636
[TBL] [Abstract][Full Text] [Related]
18. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation.
Jackevicius CA; Tsadok MA; Essebag V; Atzema C; Eisenberg MJ; Tu JV; Lu L; Rahme E; Ho PM; Turakhia M; Humphries KH; Behlouli H; Zhou L; Pilote L
Heart; 2017 Sep; 103(17):1331-1338. PubMed ID: 28286333
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT).
Bando S; Nishikado A; Hiura N; Ikeda S; Kakutani A; Yamamoto K; Kaname N; Fukatani M; Takagi Y; Yukiiri K; Fukuda Y; Nakaya Y
J Cardiol; 2018 Feb; 71(2):197-201. PubMed ID: 28969968
[TBL] [Abstract][Full Text] [Related]
20. Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
Ikeda T; Atarashi H; Inoue H; Uchiyama S; Kitazono T; Yamashita T; Shimizu W; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Sakuma I; Saku K; Okumura Y; Nakamura Y; Morimoto H; Matsumoto N; Tsuchida A; Ako J; Sugishita N; Shimizu S; Shimokawa H
Tohoku J Exp Med; 2016 Dec; 240(4):259-268. PubMed ID: 27904005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
